Clinical trial
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or…
NCT03098030 · United Therapeutics, Industry · Completed
Key facts
| NCT number | NCT03098030 |
|---|---|
| Title | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer |
| Official title | A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer |
| Lead sponsor | United Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Dinutuximab, Irinotecan, Topotecan |
| Enrollment | 483 |
| Start date | Jun 1, 2017 |
| Primary completion | Jan 27, 2020 |
| Completion | Mar 26, 2020 |
| First posted | Mar 31, 2017 |
| Last update posted | Dec 9, 2020 |
| Countries | Australia, Bulgaria, Canada, France, Georgia, Hong Kong, Hungary, India, Italy, Lithuania, Malaysia, Philippines and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: